KMT2D and chronic myelogenous leukemia, BCR-ABL1 positive: In order to further investigate the effects of TKI therapy on the expression of MLL2/KMT2D and MLL3/KMT2C, we used a pair of KCL22 CML cell lines that are either IM sensitive (KCL22S) or IM resistant (KCL22R).